Conferences - Visterra

Antibody Design and Engineering Through Integration of Computational and Experimental Methods

February 26, 2019 | Antibody Engineering & Therapeutics, Asia

Antibody Design and Engineering Through Integration of Computational and Experimental Methods

Karthik Viswanathan

Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data

January 15, 2019 | Peptalk

Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data

Andrew Wollacott

Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties

January 15, 2019 | Peptalk

Booth, et. al.

Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties

Brain J Booth, Boopathy Ramakrishnan, Kristin Narayan, Andrew M Wollacott, Danielle Wisheart, Alison Thomson, Brianna Close, Gregory J Babcock, Zachary Shriver and Karthik Viswanathan

>SEE POSTER

(Sibeprenlimab), an APRIL-Neutralizing IgG2

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference

Hershberger, et. al.

(Sibeprenlimab), an APRIL-Neutralizing IgG2

Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine Hay, Patrick Smith, Frank Engler, Jose Trevejo, Zach Shriver, David Oldach

Monoclonal Antibody, in Healthy Volunteers

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference

Narayan, et. al.

Monoclonal Antibody, in Healthy Volunteers

Kristin Narayan, Bharathi Sundaresh, Emily Helger, Andrew Wollacott, Karthik Viswanathan, Gregory Babcock, David Oldach, Susan Sloan

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference

Narayan, et. al.

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

Kristin Narayan, Bharathi Sundaresh, Emily Helger, Saskia Smits, Rienk Jeeninga, Susan Sloan, David Oldach

>SEE POSTER

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

October 23, 2018 | American Society of Nephrology (ASN)

Sloan, et. al.

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

Susan E Sloan, Frank Engler, Kristy J Szretter, James R Myette, Kristin Narayan, Bharathi L Sundaresh, Brian J G Pereira

>SEE POSTER

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

October 23, 2018 | American Society of Nephrology (ASN)

Miller, et. al.

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

Veronica M Miller, Susan E Sloan, Kristy J Szretter, James R Myette , Emily Helger, Brian J G Pereira

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

September 27, 2018 | International IgAN Symposium

Myette, et. al.

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

James R Myette, Toshiki Kano, Hitoshi Suzuki, Susan E Sloan, Yusuke Suzuki, Brian J G

>SEE POSTER

Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys

September 27, 2018 | International IgAN Symposium

Sloan, et. al.

Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys

Susan E Sloan, James R Myette, Bharathi L Sundaresh, Zachary Shriver, David Oldach, Brian J G Pereira

>SEE POSTER